These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27137103)

  • 1. New expectations in the treatment of anemia in chronic kidney disease.
    López-Gómez JM; Abad S; Vega A
    Nefrologia; 2016; 36(3):232-6. PubMed ID: 27137103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
    Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
    Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
    Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal anemia: current treatments and emerging molecules.
    Heras-Benito M
    Rev Clin Esp (Barc); 2023; 223(7):433-439. PubMed ID: 37348652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Treatment Approaches for the Anemia of CKD.
    Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
    Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON.
    Wish JB
    Am J Nephrol; 2022; 53(5):366-371. PubMed ID: 35462360
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental and investigational therapies for chemotherapy-induced anemia.
    Testa U; Castelli G; Elvira P
    Expert Opin Investig Drugs; 2015; 24(11):1433-45. PubMed ID: 26359222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
    Hasegawa S; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia management in dialysis patients: a PIVOT and a new path?
    Nair S; Trivedi M
    Curr Opin Nephrol Hypertens; 2020 May; 29(3):351-355. PubMed ID: 32235274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease?
    Locatelli F; Del Vecchio L
    Nephrol Dial Transplant; 2020 Jun; 35(6):926-932. PubMed ID: 30844045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary.
    Musio F
    Expert Rev Hematol; 2020 Nov; 13(11):1175-1188. PubMed ID: 33028115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?].
    Ryšavá R
    Vnitr Lek; 2022; 68(7):438-443. PubMed ID: 36402568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An ongoing study of anemia correction in chronic kidney disease.
    Pfeffer MA;
    N Engl J Med; 2007 Mar; 356(9):959-61. PubMed ID: 17329707
    [No Abstract]   [Full Text] [Related]  

  • 18. HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
    Wyatt CM; Drüeke TB
    Kidney Int; 2016 Nov; 90(5):923-925. PubMed ID: 27742192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.